As the RNA Oncology Company, TransCode is committed to defeating cancer through the intelligent design and effective delivery of regulatory and messenger RNA. Our modular toolbox enables rational drug design, exemplified by our lead Therapeutic Candidate TTX-MC138 which targets miR-10b for the treatment of metastatic cancer. Research & Development efforts are focused on expanding our delivery capabilities in RNAi as well as RIG-I, CRISPR, and mRNA.
Ticker:
RNAZ
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
TTX MC138
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
